Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C- MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease

Cancer

Volumn 88, Issue 9, 2000, Pages 2142-2148

  Montoto, Silvia ^a,b   Camós, Mireia ^a,b   López Guillermo, Armando ^a,b   Bosch, Francesc ^a,b   Cervantes, Francisco ^a,b   Bladé, Joan ^a,b   Esteve, Jordi ^a,b   Cobo, Francesc ^a,b   Nomdedeu, Benet ^a,b   Campo, Elías ^b   Montserrat, Emilio ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

Author keywords

C MOPP ABV; Hodgkin disease; Toxicity; Treatment

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HODGKIN DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; SECOND CANCER; SEPSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL RATE; VINBLASTINE; VINCRISTINE;

EID: 0034193154     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2142::AID-CNCR21>3.0.CO;2-M     Document Type: Article

References (35)

1. DeVita VT, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-95.
2. Urba WJ, Longo D. Hodgkin's disease. N Engl J Med 1992; 326:678-87.
3. Rosenberg SA. The management of Hodgkin's disease: half a century of change. Ann Oncol 1996;7:555-60.
4. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999;93:761-79.
5. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.
6. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med 1986;104:739-46.
7. Somers R, Carde P, Henry-Amar M, Tarayre M, Hagenbeek A, Monconduit M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994;12:279-87.
8. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985;3:1174-82.
9. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988;25(Suppl 2):34-40.
10. Khan SP, Gilchrist GS, Arndt CA, Smithson WA, Chen MG, Schomberg PJ, et al. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence. Mayo Clin Proc 1994;69:949-54.
11. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:1421-30.
12. Glick JH, Young ML, Harrington D, Schilsky L, Beck T, Neiman R, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the Intergroup Trial. J Clin Oncol 1998;16:19-26.
13. Duggan D, Petroni J, Johnson J, Hanson K, Glick J, Connors JM, et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease: a preliminary report of GALGB 8952 (with SWOG, ECOG, NCIC) [abstract]. Proc Am Soc Clin Oncol 1997;16: 12a.
14. Putterman CH, Polliack A. Late cardiovascular and pulmonary complications of therapy in Hodgkin's disease: report of three unusual cases with a review of relevant literature. Leuk Lymphoma 1992;7:109-15.
15. Polliack A. Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin's disease treated with conventional combination chemoradiotherapy. Leuk Lymphoma 1995;15(Suppl 1):7-10.
16. Kaldor JM, Day EN, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13.
17. Devereux S, Selassie TG, Vaughan Hudson G, Vaughan Hudson B, Linch DC. Leukemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. Br Med J 1990;301:1077-80.
18. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990;7:1148-54.
19. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
20. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyan R, van den Belt-Dusebut AW, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
21. van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, Hagenbeek A, Noyan R, van Kerkhoff EH, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy and bone marrow damage. J Clin Oncol 1994;12:1063-73.
22. DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
23. Henry-Amar M, Friedman S, Hayam M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease. Ann Intern Med 1991;114:361-5.
24. Connors JM, Reece DE, Diehl V, Engbert A. Hodgkin's lymphoma: new approaches to treatment. In: McArthur JR, Schechter GP, Schrier SL and Bajus JL, editors. ASH Education Program Book. Washington, DC: W.B. Saunders Co., 1998: 274-95.
25. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
26. Kaplan GL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-63.
27. 2/E in the log-rank test for survival data on tumor incidence data. Biometrics 1973;29:579-84.
28. Spector N, Costa MA, Pulcheri W, Salgado RC, Nucci M, Andrade et al. C-MOPP/ABV yields good results in a public hospital population with Hodgkin's disease in Brazil. Cancer 1993;71:2823-27.
29. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al. BEACOPP, a new dose-escalated and accelerated regimen is as least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998;16:3810-21.
30. Baez F, Ocampo E, Conter V, Flores A, Gutierrez T, Malta A, et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997;8:247-50.
31. Glimelius B, Enblad G, Kälkner M, Gustavssson A, Hakobsson M, Branehög I, et al. Treatment of Hodgkin's disease: the Swedish national care programme experience. Leuk Lymphoma 1996;21:71-8.
32. Rodríguez Diaz-Pavon J, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol 1995;13:19-27.
33. Arseneau JC, Sponzo RW, Levin DL, Schnipper LE, Bonner H, Young RC, et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy. N Engl J Med 1972;287:1119-22.
34. Van Leeuwen FE, Somers R, Taal BG, Van Heerde P, Coster B, Dozeman T, et al. Increased leukemia risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 1989;7:1046-58.
35. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathological analysis of 45 events in 37 patients. J Clin Oncol 1992;10:1674-81.